Lv2
184 积分 2023-10-09 加入
Challenges for mesenchymal stromal cell therapies
9小时前
待确认
Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies
1个月前
已完结
Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider
1个月前
已完结
iPSC衍生细胞治疗产品中的iPSC残留控制策略的实践与思考
1个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Assessments of Onset and Duration of Drug Effects and Pharmacokinetics by Dose Level of HSK3486, a New Sedative-Hypnotic Agent, in Healthy Female/Male Subjects: A Phase I Multiarm Randomized Controlled Clinical Trial
2个月前
已完结
门冬胰岛素生物类似药关键质量属性相似性评价研究
2个月前
已完结
皖公网安备34019202002308
